Lu AE58054

DRUG3 trials

Sponsors

H. Lundbeck A/S

Conditions

Alzheimer's DiseaseCognitionHealthySchizophrenia

Phase 1

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

CompletedNCT02019394

H. Lundbeck A/SHealthy

Start: 2013-12-31Updated: 2014-03-21

Phase 2

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

CompletedNCT00810667

H. Lundbeck A/SCognition, Schizophrenia

Start: 2008-11-30End: 2010-02-28Updated: 2016-11-08

Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

CompletedNCT01019421

H. Lundbeck A/SAlzheimer's Disease

Start: 2009-12-31Updated: 2012-01-06

Related Papers

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.

2014-10-05124 citations